# Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

> **NCT01605227** · PHASE3 · COMPLETED · sponsor: **Exelixis** · enrollment: 1028 (actual)

## Conditions studied

- Prostate Cancer
- Castration Resistant Prostate Cancer
- Pain
- Prostatic Neoplasms

## Interventions

- **DRUG:** cabozantinib
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT01605227
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-09
- **Final completion:** 2015-03
- **Target enrollment:** 1028 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605227, "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01605227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*